An agreement in which Abbott Laboratories will develop a specific genetic test to screen non-small cell lung cancer tumors to identify potential patients for a proposed oral cancer drug being developed by Pfizer, was hailed as an important development in the new era of personalized genomic medicine, by Avi Spira, MD. He is Associate Professor of Pathology andLaboratory Medicine.
“This is a very big step if they can first identify the subset that will benefit prior to treatment.”
Contact Avi Spria, 617-414-6980, aspira@bu.edu
